It is likely that CAF-derived TGF-β can impair the maturation of tumour dendritic cells (DCs), via blocking the expression of co-stimulatory proteins at the surface of these cells, which is necessary for the correct presentation of tumour-specific or associated antigens to reactive CD4+ T cells in secondary lymphoid tissues. Here, TGFB1 is linked to neoplasm.